| Name | Title | Contact Details |
|---|
88rising (stylized as 88⬆) is an American mass media company that founded in 2015 by Sean Miyashiro describes as a "hybrid management, record label, video production and marketing company." The company has gained popularity as a musical platform and label for Asian artists such as Keith Ape, Rich Brian, Joji, NIKI, and Higher Brothers. Headquartered in New York City, the company also has offices in Los Angeles and Shanghai. Outside of its core group, the company has collaborated with other artists such as Ghostface Killah, 21 Savage, XXXTentacion, Trippie Redd, Ski Mask the Slump God, Kris Wu, Yaeji, and others.
Placing small E&S risks shouldnt be hard. Pathpoint was built to make it faster and easier for retail agents to get great E&S coverage options. Quote and bind coverage for your small business clients online with one streamlined submission. Receive multiple bindable quotes for your clients in minutes, not days.
Insurance Quantified is a leading underwriting technology provider that arms commercial property and casualty insurance carriers and MGAs with the data and analytics they need to grow their business, improve underwriting profitability and be a preferred partner and employer. Backed by Two Sigma, a pioneer and global leader in the financial sciences, we believe that systematically delivering the right data to the right people at the right time will enable faster coverage decisions, more agile product innovation and significant risk reduction for all participants in the underwriting value chain. On June 20, 2023, Insurance Quantified acquired Groundspeed Analytics, the market leader in ingestion and data solutions to the commercial P&C industry. Together, the united technology capabilities, market success, and committed backing of Two Sigma creates an unparalleled underwriting technology partner for commercial insurers.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Were developing tech to feed the world. The world is running out of phosphorus. Most of the worlds phosphorus is used to grow food to feed to animals to produce meat. Manure isnt returned to growing regions, and instead leads to algal blooms and nutrient pollution. Were fixing this problem with tech to produce fertilizer from manure, helping farmers grow better food at a price farmers can afford.